Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 6, 2023 (February 28, 2023)

 

IMMUNE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Florida		000-54933		59-3226705
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

2431 Aloma Ave., Suite 124, Winter Park, Florida		32792
(Address of principal executive offices)		(Zip Code)

 

888-391-9355

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On February 28, 2023, shareholders holding approximately 50.58% of the outstanding common stock of Immune Therapeutics, Inc. (the “Company”) executed a written consent (the “Written Consent”) in lieu of a special meeting of the shareholders approving an amendment to the amended and restated articles of incorporation of the Company to change the Company’s name to “Biostax Corp.” (the “Articles of Amendment”). Pursuant to Rule 14c-2 of the Exchange Act of 1934, as amended, the Articles of Amendment may not become effective until at least 20 calendar days following the date on which an information statement informing shareholders of the Written Consent is first mailed to the Company’s shareholders of record.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 6, 2023	IMMUNE THERAPEUTICES, INC.
	/s/ Kelly Wilson
	Name: Kelly Wilson
	Title: Principal Executive Officer